Drug Profile

Research programme: siglecs targeted immunotherapies - T23 Biopharmaceuticals

Alternative Names: T101- T23 Biopharmaceuticals

Latest Information Update: 28 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator The Scripps Research Institute
Developer T23 Biopharmaceutical
Class Antineoplastics; Drug conjugates
Mechanism of Action Sialic acid binding immunoglobulin-like lectin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
28 Mar 2021 No recent reports of development identified for preclinical development in Cancer in USA
15 Mar 2019 Preclinical trials in Cancer and autoimmune disorders still ongoing in USA (T23 Biopharmaceuticals, March 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com